After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody–drug conjugate can be given as a single agent or in combination with chemotherapy.
from Cancer via ola Kala on Inoreader http://ift.tt/2z75rEm
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου